SNTI: Senti Biosciences Inc. Stocks News on June 5, 2025

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

SNTI

GlobeNewswire

14 days ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

SNTI

GlobeNewswire

14 days ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

SNTI

GlobeNewswire

a month ago

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

SNTI

GlobeNewswire

a month ago

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

Biotech Alert: Searches spiking for these stocks today

SNTI

TipRanks

a month ago

Biotech Alert: Searches spiking for these stocks today

Senti Bio Releases Virtual Investor “What This Means” Segment

SNTI

GlobeNewswire

a month ago

Senti Bio Releases Virtual Investor “What This Means” Segment

Senti Bio to Present at the Citizens JMP Life Sciences Conference

SNTI

GlobeNewswire

a month ago

Senti Bio to Present at the Citizens JMP Life Sciences Conference

SNTI

MT Newswires

a month ago

Top Midday Decliners

SNTI

MT Newswires

a month ago

Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall

$Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML$

SNTI

GlobeNewswire

a month ago

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

SNTI

GlobeNewswire

a month ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Senti Bio Participates in a Virtual Investor KOL Connect Segment

SNTI

GlobeNewswire

a month ago

Senti Bio Participates in a Virtual Investor KOL Connect Segment

SNTI

GlobeNewswire

2 months ago

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

SNTI

GlobeNewswire

2 months ago

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Senti Bio Joins Webull Corporate Connect Service Platform

SNTI

GlobeNewswire

2 months ago

Senti Bio Joins Webull Corporate Connect Service Platform

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

SNTI

GlobeNewswire

2 months ago

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

SNTI

MT Newswires

2 months ago

Senti Biosciences Files Shelf for 52.9 Million Shares

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

SNTI

GlobeNewswire

3 months ago

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

Senti Bio Appoints Feng Hsiung to Board of Directors

SNTI

GlobeNewswire

3 months ago

Senti Bio Appoints Feng Hsiung to Board of Directors

Senti Bio Strengthens Leadership Team with Strategic Hires

SNTI

GlobeNewswire

3 months ago

Senti Bio Strengthens Leadership Team with Strategic Hires

US Penny Stocks To Watch In January 2025

SNTI

Simply Wall St.

4 months ago

US Penny Stocks To Watch In January 2025

Senti Bio Announces Additional $11.5 Million of Financing

SNTI

GlobeNewswire

5 months ago

Senti Bio Announces Additional $11.5 Million of Financing

SNTI

MT Newswires

6 months ago

Senti Biosciences Reports First Patient Dosed in Trial of SN301A in Hepatocellular Carcinoma

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

SNTI

GlobeNewswire

6 months ago

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Bio price target raised to $12 from $10 at Chardan

SNTI

TipRanks

6 months ago

Senti Bio price target raised to $12 from $10 at Chardan

Senti Biosciences Announces New Employment Inducement Grants

SNTI

GlobeNewswire

6 months ago

Senti Biosciences Announces New Employment Inducement Grants

SNTI

Zacks

6 months ago

SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202

SNTI

TipRanks

6 months ago

Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202

SNTI

MT Newswires

6 months ago

Sector Update: Health Care Stocks Slipping Late Afternoon

SNTI

MT Newswires

6 months ago

Sector Update: Health Care Stocks Softer Monday Afternoon

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

SNTI

Benzinga

6 months ago

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

SNTI

MT Newswires

6 months ago

Senti Biosciences Says 2 Patients Achieve Remission in Phase 1 Blood Cancer Trial

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

SNTI

GlobeNewswire

6 months ago

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

$Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML$

SNTI

GlobeNewswire

6 months ago

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Bio Appoints Fran Schulz to Board of Directors

SNTI

GlobeNewswire

6 months ago

Senti Bio Appoints Fran Schulz to Board of Directors

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

SNTI

GlobeNewswire

7 months ago

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Senti Bio to Participate in Upcoming Investor Conferences

SNTI

GlobeNewswire

9 months ago

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

SNTI

GlobeNewswire

10 months ago

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

SNTI

GlobeNewswire

10 months ago

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

SNTI

MT Newswires

a year ago

Senti Biosciences Board Authorizes 1-for-10 Reverse Stock Split; Shares Fall

SNTI

GlobeNewswire

a year ago

Senti Bio Announces Reverse Stock Split

SNTI

MT Newswires

a year ago

Top Midday Gainers

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

SNTI

GlobeNewswire

a year ago

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

$Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia$

SNTI

GlobeNewswire

a year ago

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

SNTI

GlobeNewswire

a year ago

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

SNTI

GlobeNewswire

a year ago

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

SNTI

GlobeNewswire

a year ago

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

CoreCard Corporation Schedules Fourth Quarter 2023 Earnings Release and Conference Call

SNTI

GlobeNewswire

a year ago

CoreCard Corporation Schedules Fourth Quarter 2023 Earnings Release and Conference Call

Summit State Bank Reports Net Income of $10.8 Million for the Year 2023; Declares Quarterly Cash Dividend of $0.12 Per Common Share

SNTI

GlobeNewswire

a year ago

Summit State Bank Reports Net Income of $10.8 Million for the Year 2023; Declares Quarterly Cash Dividend of $0.12 Per Common Share

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

SNTI

Zacks

a year ago

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

The Mullen THREE, Class 3 EV Truck Now CARB Certified and Ready for Sale in All CARB States and District of Columbia

SNTI

GlobeNewswire

a year ago

The Mullen THREE, Class 3 EV Truck Now CARB Certified and Ready for Sale in All CARB States and District of Columbia

What Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?

SNTI

Simply Wall St.

a year ago

What Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?

ECD Auto Design's Newest Restored Defender 110 Soft Top Set to Take on Colorado Mountains

SNTI

PR Newswire

a year ago

ECD Auto Design's Newest Restored Defender 110 Soft Top Set to Take on Colorado Mountains

Caravelle's Chairman of the Board and CEO, Dr. Guohua Zhang, invited to Davos Summit 2024

SNTI

PR Newswire

a year ago

Caravelle's Chairman of the Board and CEO, Dr. Guohua Zhang, invited to Davos Summit 2024

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

SNTI

Zacks

a year ago

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

The past five years for AmeriServ Financial (NASDAQ:ASRV) investors has not been profitable

SNTI

Simply Wall St.

a year ago

The past five years for AmeriServ Financial (NASDAQ:ASRV) investors has not been profitable

Nutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders

SNTI

Simply Wall St.

a year ago

Nutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of December 2023

SNTI

GlobeNewswire

a year ago

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of December 2023

Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)

SNTI

Zacks

a year ago

Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)

2 Radio Frequency Stocks to Watch in a Challenging Industry

SNTI

Zacks

a year ago

2 Radio Frequency Stocks to Watch in a Challenging Industry

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

SNTI

GlobeNewswire

a year ago

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Individual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last week

SNTI

Simply Wall St.

a year ago

Individual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last week

Billionaire Louis Bacon’s 15 Long-Term Stock Picks

SNTI

Insider Monkey

a year ago

Billionaire Louis Bacon’s 15 Long-Term Stock Picks

Bullish Aspira Women's Health Insiders Loaded Up On US$702.9k Of Stock

SNTI

Simply Wall St.

a year ago

Bullish Aspira Women's Health Insiders Loaded Up On US$702.9k Of Stock

Northann Corp. to Meet Investors, Present Latest 3D Printing Ecosystem and Sustainable Products at TISE2024 in Las Vegas January 24th – 26th, 2024

SNTI

GlobeNewswire

a year ago

Northann Corp. to Meet Investors, Present Latest 3D Printing Ecosystem and Sustainable Products at TISE2024 in Las Vegas January 24th – 26th, 2024

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

SNTI

GlobeNewswire

a year ago

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

SNTI

Zacks

a year ago

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

SNTI

The Fly

a year ago

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

SNTI

Benzinga

a year ago

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

$Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia$